Extavia

A new interferon beta-1b available for the management of multiple sclerosis.

Extavia (interferon beta-1b) is indicated for the treatment of:

  • Patients with a single demyelinating event with an active inflammatory process severe enough to require iv corticosteroids if alternative diagnoses have been excluded and they are at high risk of developing multiple sclerosis.
  • Relapsing-remitting multiple sclerosis in patients who have had at least two relapses in the preceding two years.
  • Secondary progressive multiple sclerosis with active disease evidenced by relapses.

Interferons are an established treatment option for multiple sclerosis. The exact mechanism of action is unknown although they are throught to work through immunomodulatory effects.

View Extavia drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

New opioid warnings and fentanyl patch contraindication

New opioid warnings and fentanyl patch contraindication

New warnings about tolerance and dependence are being...

NICE updates sciatica treatment guidance

NICE updates sciatica treatment guidance

Updated NICE guidance on sciatica advises against the...